Verici Dx Plc

0.00 (0.0%)
Share Name Share Symbol Market Type Share ISIN Share Description
Verici Dx Plc LSE:VRCI London Ordinary Share GB00BM8HZD43 ORD GBP0.001
  Price Change % Change Share Price Shares Traded Last Trade
  0.00 0.0% 11.50 214,354 07:44:33
Bid Price Offer Price High Price Low Price Open Price
11.00 12.00 11.50 11.50 11.50
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Business Services, Nec 0.00 -8.33 -5.90 - 16.30
Last Trade Time Trade Type Trade Size Trade Price Currency
16:35:00 O 6 11.00 GBX

Verici Dx (VRCI) Latest News

Verici Dx (VRCI) Discussions and Chat

Verici Dx Forums and Chat

Date Time Title Posts
05/6/202309:52Verici DX- Break through immuno-diagnostic test512

Add a New Thread

Verici Dx (VRCI) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type

Verici Dx (VRCI) Top Chat Posts

Top Posts
Posted at 05/6/2023 07:36 by brummy_git
Confident & positive FY22 results & outlook from immunodiagnostics pioneer VericiDx today. All the details here.


Posted at 31/5/2023 13:06 by oapknob1
Tutivia and Clarava can be as brilliant as VRCI and the CEO say but if they don't sell they don't sell. Simple as that. (Similar to STX who have payer coverage etc)
Posted at 09/5/2023 14:23 by wan
Maybe, but not necessarily, as Verici has already stated that they are exploring strategic options to increase sales distribution and launch its second lead product, Clarava(TM) by the end of the year.

Therefore, and given what's going on in the transplant landscape, strategic partnering is another, if not a preferred option, which could be very positive for the share price on confirmation/announcement and offer sustained growth and improved shareholder value in the medium to long-term long-term, especially given the opportunities beyond kidney transplant testing alone (not to mention the low valuation compared to IPO!).

I am also looking forward to Verici's data readout from its Clarava(TM) validation trial during Q2 2023.

Posted at 06/5/2023 09:54 by wan
I note that investment bank UBS has initiated coverage of Natera with a target price of $76. Natera has a current share price of $54.50.

In a research note on Natera, UBS analysts Elizabeth Garcia and Christopher Mercado wrote that "the company is poised over the next several years to increase its penetration across three key markets: noninvasive prenatal [testing] in average risk pregnancies, minimal residual disease testing in oncology, and organ transplant monitoring."

Natera will announce its first quarter results next Tuesday -

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that it will release results for its first quarter ended March 31, 2023, after the market close on May 9, 2023. Natera will host a conference call and webcast shortly thereafter at 1:30 p.m. PT (4:30 p.m. ET).

Posted at 24/4/2023 07:53 by cliveas
I agree VRCI must surely be in the spotlight for an approach of somekind and sooner rather than later.

If Clarava results are as expected that will be 2 viable commercial tests in VRCI's back pocket.


Posted at 27/3/2023 15:00 by wooster4
If a share price rises by 100%, is the company not required to state if there is no reason for the rise. Does the absence of such a statement infer that something is brewing behind the scenes??
Posted at 22/3/2023 08:46 by toffeeman
Nothing new though Paul, so no impact on share price.

Glad my holding was EISable at the last raise! the chart is horrible.

Posted at 22/3/2023 08:03 by brummy_git
Very encouraging progress by Verici Dx.

An AI-enabled & RNA sequenced, immuno-diagnostics & data services firm for kidney transplants.

All the details here.


Posted at 17/3/2023 09:42 by wan
Given Verici's dire overall share price performance, it's certainly not a good indication as to the vast potential of Verici's kidney transplant platform!

With the share price more recently appearing to indicate that something is going to hit the fan, I keenly await reading the Chairman's commentary since reporting only in September 2022 of the 'apparent' strong progress and further stating that that progress "have left us well positioned for further progress towards commercialisation over the remainder of 2022 and beyond."

Until we get some clarification as to a clearer position, there is little point to commenting here!

Posted at 02/3/2023 07:14 by brummy_git
More positive news today from Verici Dx . A developer of next generation immuno-diagnostics for kidney transplant patients.

All the details here


Verici Dx share price data is direct from the London Stock Exchange
Your Recent History
Verici Dx
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

Log in to ADVFN
Register Now

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

Support: +44 (0) 203 8794 460 | support@advfn.com

V: D: 20230607 16:06:00